Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Swanson

Showing results (141-150 of 174) with videos related to

Pageof 18
Sort By:
Neurobiology of Disease|June 6, 2024
Microglial proliferation and astrocytic protein alterations in the human Huntington's disease cortexAdelie Y S Tan, Lynette J Tippett, Clinton P Turner, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2020
Stimulator of interferon genes (STING) is an essential proviral host factor for human rhinovirus species A and CKevin L McKnight, Karen V Swanson, Kathryn Austgen, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2016
Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivoNicole C Ammerman, Rosemary V Swanson, Asa Tapley, et al.
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.
Neurobiology of Disease|September 28, 2025
A meta-analysis of genetic variant pathogenicity and sex differences in UBQLN2-linked amyotrophic lateral sclerosis and frontotemporal dementiaKyrah M Thumbadoo, Laura R Nementzik, Molly E V Swanson, et al.
Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.
Medical and Pediatric Oncology|January 1, 1979
Childhood leukemia and lymphoma: correlation of clinical features with immunological and morphological studiesJ J Quinn, C R Taylor, V Swanson, et al.
Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Scientific Reports|May 3, 2025
Huntingtin inclusion bodies have distinct immunophenotypes and ubiquitination profiles in the Huntington's disease human cerebral cortexMolly E V Swanson, Adelie Y S Tan, Lynette J Tippett, et al.
Brain Pathology (Zurich, Switzerland)|December 20, 2023
Distribution of ubiquilin 2 and TDP-43 aggregates throughout the CNS in UBQLN2 p.T487I-linked amyotrophic lateral sclerosis and frontotemporal dementiaLaura R Nementzik, Kyrah M Thumbadoo, Helen C Murray, et al.
Pageof 18

Showing results (141-150 of 174) with videos related to

Sort By:
Pageof 18
Neurobiology of Disease|June 6, 2024
Microglial proliferation and astrocytic protein alterations in the human Huntington's disease cortexAdelie Y S Tan, Lynette J Tippett, Clinton P Turner, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 16, 2020
Stimulator of interferon genes (STING) is an essential proviral host factor for human rhinovirus species A and CKevin L McKnight, Karen V Swanson, Kathryn Austgen, et al.
The Journal of Antimicrobial Chemotherapy|November 1, 2016
Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivoNicole C Ammerman, Rosemary V Swanson, Asa Tapley, et al.
Journal of Medicinal Chemistry|September 11, 2024
Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and AchondroplasiaRobert L Hudkins, Eric Allen, Alexandra Balcer, et al.
Neurobiology of Disease|September 28, 2025
A meta-analysis of genetic variant pathogenicity and sex differences in UBQLN2-linked amyotrophic lateral sclerosis and frontotemporal dementiaKyrah M Thumbadoo, Laura R Nementzik, Molly E V Swanson, et al.
Journal of Medicinal Chemistry|March 31, 2026
Structure-Based Design of a Novel Covalent 4-(1-Methylindol-3-yl)pyrimidin-2-amine Series Targeting FGFR2 Resistance MutationsRobert L Hudkins, Eric Allen, Samhita Iyer, et al.
Medical and Pediatric Oncology|January 1, 1979
Childhood leukemia and lymphoma: correlation of clinical features with immunological and morphological studiesJ J Quinn, C R Taylor, V Swanson, et al.
Molecular Cancer Therapeutics|October 14, 2025
Dabogratinib (TYRA-300), an FGFR3 isoform-selective inhibitor: preclinical and initial clinical evidence of anti-tumor activityJacqueline H Starrett, Eric L Allen, Melissa Neal, et al.
Scientific Reports|May 3, 2025
Huntingtin inclusion bodies have distinct immunophenotypes and ubiquitination profiles in the Huntington's disease human cerebral cortexMolly E V Swanson, Adelie Y S Tan, Lynette J Tippett, et al.
Brain Pathology (Zurich, Switzerland)|December 20, 2023
Distribution of ubiquilin 2 and TDP-43 aggregates throughout the CNS in UBQLN2 p.T487I-linked amyotrophic lateral sclerosis and frontotemporal dementiaLaura R Nementzik, Kyrah M Thumbadoo, Helen C Murray, et al.
Pageof 18